清肺利咽合剂治疗肺燥阴伤型新型冠状病毒感染后急性咳嗽43例  

Clinical effect of Qingfei Liyan mixture in treatment of acute cough after severe acute respiratory syndrome COVID-19 infection with lung dryness and Yin injury:An analysis of 43 cases

作　　者：吴祥岷 杨园园 宋文采[1] WU Xiangmin;YANG Yuanyuan;SONG Wencai(Linyi Hospital of Traditional Chinese Medicine,Linyi 276002,Shandong,China)

机构地区：[1]临沂市中医医院,山东临沂276002

出　　处：《湖南中医杂志》2023年第11期1-3,53,共4页Hunan Journal of Traditional Chinese Medicine

摘　　要：目的:观察清肺利咽合剂治疗肺燥阴伤型新型冠状病毒感染(简称“新冠病毒感染”)后急性咳嗽的临床疗效。方法:将86例新冠病毒感染后急性咳嗽患者随机分为治疗组和对照组,每组各43例。对照组口服复方福尔可定溶液,治疗组口服清肺利咽合剂,2组均连续治疗1周。比较2组临床疗效、简易咳嗽程度评分表(CET)积分及不良反应发生率。结果:总有效率治疗组为93.02%(40/43),对照组为74.42%(32/43),2组比较,差异有统计学意义(P<0.05);治疗后2组CET积分均低于治疗前,且治疗组低于对照组(P<0.05);不良反应发生率治疗组为2.33%(1/43),低于对照组的16.28%(7/43),差异有统计学意义(P<0.05)。结论:清肺利咽合剂治疗肺燥阴伤型新冠病毒感染后急性咳嗽的疗效优于西药治疗,且不良反应较少,安全性高。Objective:To investigate the clinical effect of Qingfei Liyan mixture in the treatment of acute cough after severe acute respiratory syndrome COVID-19 infection with lung dryness and Yin injury.Methods:A total of 86 patients with acute cough after COVID-19 infection were randomly divided into treatment group and control group,with 43 patients in each group.The patients in the control group were given oral administration of compound pholcodine solution,while those in the treatment group were given oral administration of Qingfei Liyan mixture,and both groups were treated for 1 week.The two groups were compared in terms of clinical efficacy,Cough Evaluation Test(CET)score,and the incidence rate of adverse reactions.Results:There was a significant difference in overall response rate between the treatment group and the control group[93.02%(40/43)vs 74.42%(32/43),P<0.05].After treatment,both groups had a reduction in CET score,and the treatment group had a significantly lower CET score than the control group(P<0.05).There was a significant difference in the incidence rate of adverse reactions between the treatment group and the control group[2.33%(1/43)vs 16.28%(7/43),P<0.05].Conclusion:Qingfei Liyan mixture has a better clinical effect than Western medicine in the treatment of acute cough after COVID-19 infection with lung dryness and Yin injury,with few adverse reactions and a favorable safety profile.

关 键 词：新冠病毒感染 急性咳嗽 中医药疗法 清肺利咽合剂 

分 类 号：R256.11[医药卫生—中医内科学]